Annika Kim Constantino
Health and Pharmaceutical Reporter at CNBC
health & pharmaceutical reporter @cnbc | signal: annikakimc.14 | @ucberkeley & @dailycal alum
Articles
-
6 days ago |
nbcwashington.com | Ashley Capoot |Bertha Coombs |Annika Kim Constantino
A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Pharma's on edge, and for good reason. Drugmakers are bracing for the ripple effects of President Donald Trump's planned tariffs on pharmaceuticals imported into the U.S. It's still unclear what exactly those levies will look like or when they'll be announced.
-
6 days ago |
nbcchicago.com | Ashley Capoot |Bertha Coombs |Annika Kim Constantino
A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Pharma's on edge, and for good reason. Drugmakers are bracing for the ripple effects of President Donald Trump's planned tariffs on pharmaceuticals imported into the U.S. It's still unclear what exactly those levies will look like or when they'll be announced.
-
1 week ago |
telemundodenver.com | Annika Kim Constantino
Los aranceles que el presidente Donald Trump planea imponer a los productos farmacéuticos importados a EEUU podrían tener consecuencias de gran alcance para las farmacéuticas y los pacientes estadounidenses, según informaron algunos expertos a la CNBC. Los aranceles podrían interrumpir la compleja cadena de suministro farmacéutica, incrementar los precios de los medicamentos en EEUU y agravar la escasez de medicamentos críticos, según advirtieron algunos expertos en políticas sanitarias.
-
1 week ago |
cnbc.com | Annika Kim Constantino
President Donald Trump's planned tariffs on pharmaceuticals imported into the U.S. could have wide-ranging consequences for drugmakers and American patients, some experts told CNBC. The duties could disrupt the complex pharmaceutical supply chain, drive up the prices of drugs in the U.S. and exacerbate shortages of critical medicines, some health policy experts said. Drugmakers often rely on a global network of manufacturing sites for different steps of the production process.
-
1 week ago |
cnbc.com | Annika Kim Constantino |Ashley Capoot
A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. President Donald Trump doubled down on plans to soon impose "major" tariffs on pharmaceuticals imported into the U.S. It comes after drugmakers breathed a temporary sigh of relief last week, when Trump exempted the sector from his big round of so-called reciprocal tariffs.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 1K
- Tweets
- 381
- DMs Open
- Yes
A mini scoop on cuts at the FDA: The FDA has gutted an entire division that trains agency staff + outside healthcare professionals on key public health, regulation and safety practices, such as opioid safety and avoiding drug errors, CNBC has learned. https://t.co/O2LFYCWfR0
RT @EamonJavers: One big point amid all the headlines: I was texting with press secretary Karoline Leavitt during the event and she confirm…
White House says pharmaceutical products will NOT be subject to the reciprocal tariffs just announced. But Trump has not ruled out his plans to impose pharmaceutical-specific tariffs sometime soon. https://t.co/EcqGrEwNbh